Treating VVA improves symptom severity and patient-reported outcomes: 6-month PEONY results

被引：0

作者：

Nappi, Rossella E. ^{[1
,2
]}

Meriggiola, Maria Cristina ^{[3
]}

Albani, Francesca ^{[4
]}

Bonaccorsi, Gloria ^{[5
]}

Carpini, Giovanni Delli ^{[6
]}

Gambera, Alessandro ^{[7
]}

Marsini, Silvia ^{[8
]}

Nicolucci, Antonio ^{[9
]}

Rossi, Maria Chiara ^{[9
]}

Trionfera, Valentina ^{[8
]}

Villa, Paola ^{[10
]}

机构：

[1] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy

[2] IRCCS S Matteo Fdn, Res Ctr Reprod Med & Gynecol Endocrinol, Menopause Unit, Piazzale Golgi 2, I-27100 Pavia, Italy

[3] IRCCS Azienda Osped Univ Bologna, Div Gynecol & Human Reprod Physiopatol, Bologna, Italy

[4] Ist Clin Sci Maugeri IRCCS, Gynecol Endocrinol Clin, Unit Endocrinol & Metab Dis, Pavia, Italy

[5] Univ Ferrara, Menopause & Osteoporosis Ctr, Ferrara, Italy

[6] Univ Politecn Marche, Dept Odontostomatol & Specialized Clin Sci, Gynecol Sect, Ancona, Italy

[7] Univ Brescia, ASST Sped Civili, Unit Gynecol Endocrinol, Brescia, Italy

[8] Shionogi Srl, Rome, Italy

[9] CORESEARCH Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy

[10] Fdn Policlin Univ Agostino Gemelli IRCCS, Dipartimento Sci Salute Donna & Bambino & San Pubb, UOC Ginecol Oncol, Rome, Italy

来源：

CLIMACTERIC | 2025年 / 28卷 / 02期

关键词：

Vulvo-vaginal atrophy; local estrogens; non-hormonal local treatments; ospemifene; breast cancer; VULVO-VAGINAL ATROPHY; QUALITY-OF-LIFE; BREAST-CANCER SURVIVORS; FEMALE SEXUAL FUNCTION; GENITOURINARY SYNDROME; INDEX FSFI; WOMEN; MANAGEMENT; MENOPAUSE; HEALTH;

D O I：

10.1080/13697137.2025.2455167

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

ObjectiveThe real-world PatiEnt satisfactiON studY (PEONY) involves postmenopausal women already treated or starting local estrogen therapy (LET) or ospemifene. The aim of the present analysis was to assess treatment satisfaction and persistence, effectiveness and patient-reported outcomes (PROs) in sexual function and quality of life after 6 months of therapy with LET or ospemifene to treat vulvovaginal atrophy (VVA).MethodsPEONY is an ongoing prospective, observational study conducted in 17 gynecology centers. Participants complete questionnaires at baseline (T0) and after 3 months (T3) and 6 months (T6). The main outcome measures were treatment satisfaction, severity of symptoms, Day-to-Day Impact of Vaginal Aging (DIVA), Female Sexual Function Index (FSFI), Female Sexual Distress Scale - Revised (FSDS-R) and SF-12 Health Survey.ResultsOverall, 385 women were included, of whom 145 started (87.6%) or continued (12.4%) ospemifene and 240 started (66.7%) or continued (33.3%) LET at T0. The likelihood of moderate/severe VVA symptoms decreased by 70-90% and the mean treatment satisfaction score increased overall from 7.3 (95% confidence interval [CI]: 7.0; 7.5) at T3 to 7.7 (95% CI: 7.4; 7.9) at T6 (p = 0.003). DIVA and FSDS-R scores significantly improved in both groups.ConclusionsPEONY underlines the importance of proactively treating VVA with LET or ospemifene to alleviate the burden associated with the disease. (sic)(sic): (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(PEONY)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(LET)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)LET(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(VVA)6(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(PROs).(sic)(sic): PEONY(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)17(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(T0),(sic)(sic)3(sic)(sic)(T3)(sic)(sic)(sic)6(sic)(sic)(T6)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic),(sic)(sic)(sic)(sic)(sic)(sic),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(DIVA),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(FSFI),(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(FSDS-R)(sic)SF-12(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic): (sic)(sic)(sic)(sic)(sic)(sic)385(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)145(sic)(sic)T0(sic)(sic)(sic)(87.6%)(sic)(sic)(sic)(12.4%)(sic)(sic)(sic)(sic)(sic)(sic), 240(sic)(sic)(sic)(66.7%)(sic)(sic)(sic)(33.3%)(sic)(sic)LET.(sic)(sic)6(sic)(sic)(sic), (sic)(sic)(sic)VVA(sic)(sic)(sic)(sic)(sic)(sic)(sic)70%-90%, (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)T3(sic)(sic)7.3(95%(sic)(sic)(sic)(sic)[CI]: 7.0;7.5)(sic)(sic)(sic)T6(sic)(sic)7.7(95% CI: 7.4;7.9)(p = 0.003).DIVA(sic)FSDS-R(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic): PEONY(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(LET)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(VVA)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).

引用

页码：115 / 125

页数：11

共 41 条

[11] Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project
Gandek, B
Ware, JE
Aaronson, NK
Apolone, G
Bjorner, JB
Brazier, JE
Bullinger, M
Kaasa, S
Leplege, A
Prieto, L
Sullivan, M
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) : 1171 - 1178
[12] Huang AJ, 2015, MENOPAUSE, V22, P144, DOI [10.1097/gme.0000000000000281, 10.1097/GME.0000000000000281]
[13] A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative
Lensen, Sarah
Bell, Robin J.
Carpenter, Janet S.
Christmas, Monica
Davis, Susan R.
Giblin, Karen
Goldstein, Steven R.
Hillard, Tim
Hunter, Myra S.
Iliodromiti, Stamatina
Jaisamrarn, Unnop
Khandelwal, Sunila
Kiesel, Ludwig
Kim, Bobae V.
Lumsden, Mary Ann
Maki, Pauline M.
Mitchell, Caroline M.
Nappi, Rossella E.
Niederberger, Craig
Panay, Nick
Roberts, Helen
Shifren, Jan
Simon, James A.
Stute, Petra
Vincent, Amanda
Wolfman, Wendy
Hickey, Martha
[J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2021, 28 (08): : 859 - 866
[14] Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women
Levine, Kristen B.
Williams, Rachel E.
Hartmann, Katherine E.
[J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (04): : 661 - 666
[15] Vulvovaginal atrophy in women with and without a history of breast cancer: Baseline data from the PatiEnt satisfactiON studY (PEONY) in Italy
Meriggiola, Maria Cristina
Villa, Paola
Maffei, Silvia
Becorpi, Angelamaria
Di Paolantonio, Tiziana
Nicolucci, Antonio
Salvatore, Stefano
Nappi, Rossella E.
[J]. MATURITAS, 2024, 183
[16] Different local estrogen therapies for a tailored approach to GSM
Nappi, R. E.
Tiranini, L.
Martini, E.
Bosoni, D.
Cassani, C.
Cucinella, L.
[J]. CLIMACTERIC, 2023, 26 (04) : 361 - 366
[17] Nappi RE, 2016, CLIMACTERIC, V19, P188, DOI 10.3109/13697137.2015.1107039
[18] Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause
Nappi, R. E.
Palacios, S.
[J]. CLIMACTERIC, 2014, 17 (01) : 3 - 9
[19] Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey
Nappi, R. E.
Kokot-Kierepa, M.
[J]. CLIMACTERIC, 2012, 15 (01) : 36 - 44
[20] Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice
Nappi, Rossella E.
Albani, Francesca
Vaccaro, Patrizia
Gardella, Barbara
Salonia, Andrea
Chiovato, Luca
Spinillo, Arsenio
Polatti, Franco
[J]. GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (04) : 214 - 219

← 1 2 3 4 5 →